Biogen Agrees To One Of Largest FCA Settlements Without DOJ Intervention

Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.

Whistleblower
Biogen agrees to settle whistleblower suit alleging it provided kickbacks to get physicians to prescribe its multiple sclerosis drugs • Source: Shutterstock

More from Marketing & Advertising

More from Compliance